In general, patients with estrogen receptor positive (ER+), Her2 receptor negative (HER2-) breast cancer, have good prognosis and the incremental benefit of adding adjuvant CT to endocrine therapy (ET) is limited. Here, ERBB2 is linked to breast cancer.